Re: ASCO and pharmacometrics
Dear Dennis, Joga, Naoto-san and All
Dennis, I fully agree with your two comments .
Concerning my mail, I should have written: the abstract "corrected by
clinicians challenging **up to** the last comma and p-value." Which means they
did much more than looking at commas, which by the end greatly improved the
abstract. They valued the work, care about science, wanted to understand and by
the end improved the abstract to give it all chances.
I fully concur also with Joga and believe this is the path to follow.
Kind regards
Pascal
Envoy? de mon iPhone
Le 7 avr. 2016 ? 19:11, Dennis Fisher
<[email protected]<mailto:[email protected]>> a ?crit :
I agree with Phil. I have presented recently at two large endocrine meetings,
one in the US, one in Europe. In both cases, I took complicated PK/PD models
and kept it simple, emphasizing how the models could / would be used in
clinical development and clinical practice. The response at both meetings was
excellent - lots of people expressing interest in the models (and,
interestingly, two of the competitors to the company for which I was consulting
tried to enlist my consulting help).
And, I disagree with Nick's comment yesterday. Perhaps oncology clinicians are
concerned about commas (I cannot speak to that issue) but I truly doubt Nick's
claim that they don't care about science - the advances in oncology in recent
years have been remarkable.
Dennis Fisher MD
P < (The "P Less Than" Company)
Phone: 1-866-PLessThan (1-866-753-7784)
Fax: 1-866-PLessThan (1-866-753-7784)
http://www.plessthan.com/
Quoted reply history
On Apr 7, 2016, at 7:49 AM, Lowe, Phil
<[email protected]<mailto:[email protected]>> wrote:
I would echo Pascal's point. Getting pharmacometric work into large clinical
conferences is not straightforward. It can be done (see
link) http://erj.ersjournals.com/content/46/suppl_59/PA5091.abstract but note
where I was in the author list as the sole modeller. It helps to work closely
with the clinicians on the messaging. That said, it was fun at the meeting,
explaining the data and model curves to clinicians with them asking how such
knowledge could impact their patients. An eye-opener. Keep trying Naoto!
All the best, Phil
Philip J Lowe PhD
Executive Director Pharmacometrics Scientist
Novartis Pharma AG, WSJ-027.6.25 or WSJ-386.12.48.46
4056 Basel, Switzerland
Phone: +41 61 324 4676
[email protected]<mailto:[email protected]>
From: [email protected]<mailto:[email protected]>
[mailto:[email protected]] On Behalf Of Pascal Girard
Sent: 06 April 2016 10:39
To: Naoto Hayashi; [email protected]<mailto:[email protected]>
Cc: nmusers
Subject: RE: [NMusers] ASCO and pharmacometrics
Dear Naoto,
In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is
our "champion" !
I got one accepted on model for Exp-Tumor Size - OS at European Cancer Congress
2013 . But I can tell you that a medical writer rewrote it entirely and it took
1 month to get it reviewed and corrected by clinicians challenging every comma
and p-value.
To give you an idea of the respective size of the meetings: ACOP N=500, PAGE
N>600, ECC N> 10,000, ASCO N>20,000.
So the advice I would give, is just improve the quality and readability of our
abstract and it will make it. By readability, I mean show it to an oncologist
clinician. If he does not understand, rewrite it with the help of a medical
writer ...
With best regards / Mit freundlichen Gr??en / Cordialement
Pascal
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or disclose the contents to any other
person. If you have received this transmission in error, please notify the
sender immediately and delete the message and any attachment from your system.
Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept
liability for any omissions or errors in this message which may arise as a
result of E-Mail-transmission or for damages resulting from any unauthorized
changes of the content of this message and any attachment thereto. Merck KGaA,
Darmstadt, Germany and any of its subsidiaries do not guarantee that this
message is free of viruses and does not accept liability for any damages caused
by any virus transmitted therewith.
Click http://www.merckgroup.com/disclaimer to access the German, French,
Spanish and Portuguese versions of this disclaimer.